Lipella Pharmaceuticals (LIPO) Revenue & Revenue Breakdown
Lipella Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$449.62M
Latest Revenue (Q)
$136.43M
Main Segment (Y)
Grant Revenues
Lipella Pharmaceuticals Revenue by Period
Lipella Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $449.62M | 244050.07% |
2022-12-31 | $184.16K | -28.99% |
2021-12-31 | $259.35K | -73.03% |
2020-12-31 | $961.68K | 38.42% |
2019-12-31 | $694.75K | - |
Lipella Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $136.43M | 93422.76% |
2024-03-31 | $145.88K | 20.72% |
2023-12-31 | $120.84K | -99.88% |
2023-09-30 | $104.05M | -2.46% |
2023-06-30 | $106.68M | 90266.63% |
2023-03-31 | $118.05K | -21.83% |
2022-12-31 | $151.01K | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | -100.00% |
2022-03-31 | $33.15K | 28.08% |
2021-12-31 | $25.88K | 100.00% |
2021-09-30 | - | -100.00% |
2021-06-30 | $148.97K | 76.30% |
2021-03-31 | $84.50K | - |
Lipella Pharmaceuticals Revenue Breakdown
Lipella Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 22 |
---|---|
Grant Revenues | $184.16K |
Quarterly Revenue by Product
Product/Service | Sep 23 | Mar 23 |
---|---|---|
Grant Revenues | $104.05K | $118.05K |
Lipella Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Mar 23 |
---|---|
Grant Revenues | $118.05K |
Lipella Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
LIPO | Lipella Pharmaceuticals | $449.62M | $136.43M |
FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
ICCC | ImmuCell | $17.47M | $7.26M |
SNTI | Senti Biosciences | $2.56M | - |
INBX | Inhibrx Biosciences | $1.80M | - |
ANEB | Anebulo Pharmaceuticals | - | - |
ELYM | Eliem Therapeutics | - | - |
ACRV | Acrivon Therapeutics | - | - |
CELC | Celcuity | - | - |
MNPR | Monopar Therapeutics | - | - |
MACK | Merrimack Pharmaceuticals | - | - |
PTIX | Protagenic Therapeutics | - | - |
ELVN | Enliven Therapeutics | - | - |
LIPO Revenue FAQ
What is Lipella Pharmaceuticals’s yearly revenue?
Lipella Pharmaceuticals's yearly revenue for 2023 was $449.62M, representing an increase of 244050.07% compared to 2022. The company's yearly revenue for 2022 was $184.16K, representing a decrease of -28.99% compared to 2021. LIPO's yearly revenue for 2021 was $259.35K, representing a decrease of -73.03% compared to 2020.
What is Lipella Pharmaceuticals’s quarterly revenue?
Lipella Pharmaceuticals's quarterly revenue for Q2 2024 was $136.43M, a 93422.76% increase from the previous quarter (Q1 2024), and a 27.89% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $145.88K, a 20.72% increase from the previous quarter (Q4 2023), and a 23.58% increase year-over-year (Q1 2023). LIPO's quarterly revenue for Q4 2023 was $120.84K, a -99.88% decrease from the previous quarter (Q3 2023), and a -19.98% decrease year-over-year (Q4 2022).
What is Lipella Pharmaceuticals’s revenue growth rate?
Lipella Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 173265.03%, and for the last 5 years (2019-2023) was 64616.56%.
What are Lipella Pharmaceuticals’s revenue streams?
Lipella Pharmaceuticals's revenue streams in c 22 are Grant Revenues
What is Lipella Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Lipella Pharmaceuticals was Grant Revenues. This segment made a revenue of $184.16K, representing 100.00% of the company's total revenue.